Celgene Amgen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Investors, whether u. S. Stocks are really still the place to be and lets waek in jeremy with us once again live from philadelphia. Professor, welcome back. Good afternoon, scott. Professor schiller at the beginning of the week saying stocks could go up another 50 from here. What do you say . I said are you bullish . It could go up 50 . It could go down 50 . The word could does not really mean that thats what he expects. But you know, the momentum is there. The earnings momentum is is there. I think actually its very, the dollar being down is very positive. Especially for the s p 500. Thats wh...

Riding a bicycle. If you told me two weeks ago that apple was going to rally 7 , crude woul see losses of 13 and biotech stocks would rally 13 , id say youre crazy. What is going on here, tim . Lets talk about apple quickly. I dont think anything changed with their business, a although we got an earnings print, if you lins to the community, one of the things theyre saying is they can they think trade at a higher multiple. Anywhere from 13 to 14 depending on what the e prk s outlook is. Because the growth is better. Were getting into a period where you have this refresh cycle and inn some of th...

Patients are driving the push away from needles, and there are a number of novel approaches attempting to solve the difficult task of transforming biologics into orally administered treatments.

With no unexpected signals, a recent review of tralokinumab safety out to 1 year found no unexpected signals and provided some information about potential advantages of flexible dosing.